Research programme - cystic fibrosis therapeutics - GENSAIC
Latest Information Update: 19 Dec 2022
At a glance
- Originator M13 therapeutics
- Developer GENSAIC
- Class Antifibrotics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cystic fibrosis